Evidence map›Paper›PMID 24915210›Full record

Trial reportInfection control and hospital epidemiology2014

Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution.

Michael Phillips, Andrew Rosenberg, Bo Shopsin, Germaine Cuff, Faith Skeete, Alycia Foti, Kandy Kraemer, Kenneth Inglima, Robert Press, Joseph Bosco

3 registry-linked trialsAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Infection control and hospital epidemiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 54 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01313182 phase4completednot on this map

Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine

TypeinterventionalSponsorSolventum US LLCRan2011 to 2012Enrolled1,874ConditionsSurgical Site InfectionArmsmupirocin calcium ointment, 2%, 3M Skin and Nasal Antiseptic
NCT03605498 completednot on this mapstarted 2017, after this paper: background citation

An Investigation of Novel Technology to Bring Genomic Analysis to the Patient Bedside to Systematically Track and Report on ESKAPE Bacterial Transmission in Today's Operating Room Environments

TypeobservationalSponsorSundara ReddyRan2017 to 2018Enrolled83ConditionsBacterial Infections
NCT04299737 withdrawnnot on this mapstarted 2020, after this paper: background citation

Improving Case Selection for Perioperative S. Aureus Transmission Surveillance to Reduce Surgical Site Infections

TypeobservationalSponsorRandy LoftusRan2020 to 2021Enrolled0ConditionsS. Aureus TransmissionArmsTreatment Bundle (as defined below)
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Universal decolonization for methicillin-resistantPublic health in practice (Oxford, England) · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Intranasal Testing and Treatment forJournal of the Pediatric Orthopaedic Society of North America · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael PhillipsNew York University Hospital Center, New York, New York.
Andrew Rosenberg
Bo Shopsin
Germaine Cuff
Faith Skeete
Alycia Foti
Kandy Kraemer
Kenneth Inglima
Robert Press
Joseph Bosco

Funding

Role of precipitous virulence in invasiveness of community-acquired methicillin-rR01AI103268 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SHOPSIN, BO, TORRES, VICTOR J. · 2013 to 2017
$2.1M
NIAID NIH HHS R01 AI103268NIAID NIH HHS R01 AI103268-01
6 · The paper itself

Abstract

backgroundTreatment of Staphylococcus aureus colonization before surgery reduces risk of surgical site infection (SSI). The regimen of nasal mupirocin ointment and topical chlorhexidine gluconate is effective, but cost and patient compliance may be a barrier. Nasal povidone-iodine solution may provide an alternative to mupirocin.

methodsWe conducted an investigator-initiated, open-label, randomized trial comparing SSI after arthroplasty or spine fusion in patients receiving topical chlorhexidine wipes in combination with either twice daily application of nasal mupirocin ointment during the 5 days before surgery or 2 applications of povidone-iodine solution into each nostril within 2 hours of surgical incision. The primary study end point was deep SSI within the 3 months after surgery.

resultsIn the modified intent-to-treat analysis, a deep SSI developed after 14 of 855 surgical procedures in the mupirocin group and 6 of 842 surgical procedures in the povidone-iodine group (P = .1); S. aureus deep SSI developed after 5 surgical procedures in the mupirocin group and 1 surgical procedure in the povidone-iodine group (P = .2). In the per protocol analysis, S. aureus deep SSI developed in 5 of 763 surgical procedures in the mupirocin group and 0 of 776 surgical procedures in the povidone-iodine group (P = .03).

conclusionsNasal povidone-iodine may be considered as an alternative to mupirocin in a multifaceted approach to reduce SSI.

trial registrationClinicalTrials.gov identifier: NCT01313182.

Indexed as

Antibiotic ProphylaxisAdministration, IntranasalAdultAgedAged, 80 and overAnti-Bacterial AgentsArthroplastyFemaleHumansIntention to Treat AnalysisMaleMiddle AgedMupirocinNoseOintmentsPovidone-IodineAnti-Bacterial AgentsMupirocinOintmentsPovidone-Iodine

Identifiers

PMID24915210
PMCPMC4668802

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.